Key highlights
- Achieved 41.4% reduction in whole-blood metal-free PPIX compared to placebo with high statistical significance
- Increased average monthly total time in light without pain by 12.2 hours during the six-month study period
- Successfully met all secondary endpoints, including significant reductions in phototoxic reaction incidence rates
- Maintained a favorable safety profile with dizziness being the most commonly reported transient adverse event
- NDA resubmission for bitopertin targeted for year-end 2026 with an anticipated FDA decision by mid-2027
Phase 3 APOLLO Trial Outcomes
Disc Medicine announced that its pivotal Phase 3 APOLLO trial of bitopertin met its co-primary and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The study randomized 183 participants to receive either 60 mg of oral bitopertin or a placebo daily for six months. Results showed a 41.4% reduction in metal-free protoporphyrin IX (PPIX) levels relative to the placebo group. Additionally, patients treated with bitopertin experienced a statistically significant increase of 12.2 hours in average monthly pain-free light exposure. These findings validate the mechanism of targeting heme synthesis to address the fundamental cause of EPP-related phototoxicity.
Safety and Regulatory Timeline
The safety profile observed in the APOLLO trial was consistent with previous clinical data, showing no new safety signals or adverse events above Grade 3. Dizziness was the most frequent treatment-emergent adverse event, reported by 50% of the bitopertin group, though it was characterized as mild or moderate and generally transient. Following these positive results, Disc Medicine intends to resubmit its New Drug Application (NDA) to the FDA by the conclusion of 2026. This resubmission is expected to trigger a regulatory decision by mid-2027, potentially addressing the requirements established in the previous Complete Response Letter.
Company Operations and Portfolio
- Disc Medicine specializes in developing therapies for serious hematologic diseases by targeting iron metabolism and heme biosynthesis.
- Bitopertin is a first-in-class, oral GlyT1 inhibitor designed to modulate the production of toxic protoporphyrin IX.
- The company is also advancing DISC-3405 for polycythemia vera and DISC-0974 for anemia associated with chronic inflammatory diseases.
- Research efforts are supported by a global clinical footprint including sites in the United States, Canada, Europe, and Australia.
Financial and Strategic Context
As a clinical-stage biotechnology firm, Disc Medicine does not currently record revenue from commercial product sales. However, the company maintains a strong balance sheet with approximately $718 million in cash, cash equivalents, and marketable securities as of June 30, 2026. Management has indicated that this capital position provides a liquidity runway into 2029, covering the anticipated commercial launch of bitopertin. The firm has also secured non-dilutive financing, including a $200 million term loan facility from Hercules Capital, to ensure flexibility as it transitions toward potential commercialization in the rare disease market.
Up 34.7% since our story on 19 Oct: $56.84 when we broke it → $76.59 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $78.93 |
|---|---|
| 20 Oct | $79.48 |
| 21 Oct | $76.00 |
| 22 Oct | $75.03 |
| 23 Oct | $74.51 |
| 26 Oct | $77.66 |
| 27 Oct | $79.90 |
| 28 Oct | $83.20 |
| 29 Oct | $82.84 |
| 30 Oct | $80.84 |
| 2 Nov | $78.62 |
| 3 Nov | $81.16 |
| 4 Nov | $83.28 |
| 5 Nov | $78.47 |
| 6 Nov | $78.91 |
| 9 Nov | $81.26 |
| 10 Nov | $84.64 |
| 11 Nov | $87.08 |
| 12 Nov | $83.23 |
| 13 Nov | $80.00 |
| 16 Nov | $76.59 |
Executive Perspective
“Today represents a potential breakthrough in the science and treatment of EPP. We could not have hoped for a better outcome, and we are grateful to the patients, caregivers, and physicians who have partnered with us throughout the clinical development of bitopertin.”
| Date | Announcement | Amount |
|---|---|---|
| 09 Sep 2026 | Initial results from the Phase 2 RESTORE-PV trial of DISC-3405 in polycythemia vera presented at SOHO 2026Source: ir.discmedicine.com | – |
| 09 Jun 2026 | Regulatory update on FDA Type A meeting aligning Phase 3 APOLLO trial to support bitopertin CRL responseSource: ir.discmedicine.com | – |
| 13 Feb 2026 | Receipt of FDA Complete Response Letter for bitopertin NDA in erythropoietic protoporphyriaSource: ir.discmedicine.com | – |
| 21 Oct 2025 | Pricing of upsized public offering of common stock and pre-funded warrantsSource: ir.discmedicine.com | $250.0 Million |
| 22 Jan 2025 | Pricing of upsized public offering of common stock and pre-funded warrantsSource: ir.discmedicine.com | $225.5 Million |
| 08 Nov 2024 | Agreement for non-dilutive term loan facility from Hercules CapitalSource: ir.discmedicine.com | $200.0 Million |
Management commentary
“Today represents a potential breakthrough in the science and treatment of EPP. We could not have hoped for a better outcome, and we are grateful to the patients, caregivers, and physicians who have partnered with us throughout the clinical development of bitopertin.”
“These results are compelling evidence of the clinical benefit of a mechanism aimed at reducing the production of PPIX, the fundamental cause of disease. It has been an incredible journey from establishing the original hypothesis of targeting heme synthesis in cellular models to seeing that biology translate into the clear and meaningful clinical effects from APOLLO.”
| Share price | $56.84 |
|---|---|
| Market cap | $2.2B |
| 1-month price change | -17.11% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Disc Medicine, Inc. announcing topline results from the Phase 3 APOLLO trial of bitopertin.
Track Disc Medicine, Inc. live
Get the next Disc Medicine, Inc. SEC filing seconds after it lands.
